Delayed linkage to HIV care among asylum seekers

Kronfli, N., Linthwaite, B., Sheehan, N. et al. Delayed linkage to HIV care among asylum seekers in Quebec, CanadaBMC Public Health 191683 (2019). https://doi.org/10.1186/s12889-019-8052-y

Abstract:

Background

Migrants represent an increasing proportion of people living with HIV in many developed countries. We aimed to describe the HIV care cascade and baseline genotypic resistance for newly diagnosed asylum seekers referred to the McGill University Health Centre (MUHC) in Montreal, Quebec, Canada.

Methods

We conducted a retrospective cohort study of patients linked to the MUHC from June 1, 2017 to October 31, 2018. We calculated the median time (days; interquartile range (IQR)) from: 1) entry into Canada to immigration medical examination (IME) (i.e. HIV screening); 2) IME to patient notification of diagnosis; 3) notification to linkage to HIV care (defined as a CD4 or viral load (VL) measure); 4) linkage to HIV care to combination antiretroviral therapy (cART) prescription; and 5) cART prescription to viral suppression (defined as a VL < 20 copies/mL). We reviewed baseline genotypes and interpreted mutations using the Stanford University HIV Drug Resistance Database. We calculated the proportion with full resistance to > 1 antiretroviral.

Results

Overall, 43% (60/139) of asylum seekers were newly diagnosed in Canada. Among these, 62% were late presenters (CD4 < 350 cells/μl), 22% presented with advanced HIV (CD4 < 200 cells/μl), and 25% with high-level viremia (VL > 100,000 copies/ml). Median time from entry to IME: 27 days [IQR:13;55]; IME to notification: 28 days [IQR:21;49]; notification to linkage: 6 days [IQR:2;19]; linkage to cART prescription: 11 days [IQR:6;17]; and cART to viral suppression: 42 days [IQR:31;88]; 45% were linked to HIV care within 30 days. One-fifth (21%) had baseline resistance to at least one antiretroviral agent; the K103 N/S mutation was the most common mutation.

Conclusions

While the majority of newly diagnosed asylum seekers were late presenters, only 45% were linked to care within 30 days. Once linked, care and viral suppression were rapid. Delays in screening and linkage to care present increased risk for onward transmission, and in the context of 21% baseline resistance, consideration of point-of-care testing and immediate referral at IME screening should be made.

New HIV Treatment factsheet series

NAPWHA, 20 Dec 2018

NAPWHA would like to thank ViiV Healthcare for an unrestricted grant to produce a new range of treatment messages.

These are ideal for someone who has been newly diagnosed, or who is unsure if they are receiving the best possible treatment for them.

Below are the first three of the series; these are downloadable in PDF format.

Please continue to check in with NAPWHA in 2019 for the next in the series.

  • Download factsheets

Two cases of multi-drug resistant gonorrhoea recently detected in Australia: media release

Professor Brendan Murphy, Commonwealth Chief Medical Officer, Australian Government Department of Health 

17 April 2018

Two cases of multi-drug resistant gonorrhoea have been recently detected in Australia. One case was diagnosed in Western Australia and a second case diagnosed in Queensland. 

Multi-drug resistant strains can be difficult to treat and it is important to prevent further spread.

Evidence suggests that one of the Australian cases acquired their infection in Southeast Asia.

The situation is being closely monitored by public health authorities.

Syphilis jumps to WA: doctors say ‘complacent’ safe sex attitudes to blame

ABC News, 17/03/2018

Some sexually transmitted diseases are on the rise in Western Australia, with Aboriginal communities in the north hit particularly hard by a syphilis outbreak.

Australian Medical Association president Omar Khorshid said Aboriginal people in the north had been failed.

“It’s really sad that we’ve actually had and outbreak of syphilis that started in north Queensland that’s gone right across the north of Australia, through the Northern Territory and into the Kimberley through our Aboriginal populations,” Dr Khorshid said.

“In this day and age, in a medical system that’s had a cure for that condition for many decades, the fact we are still seeing an outbreak of such an easily treated infectious disease really says a lot about our failure as a community to deal with the health issues in our Aboriginal communities.”

 

 

Gonorrhoea ‘super-superbugs’ triple in six months [in Australia]

SMH, 13/02/2018

Cases of a strain of gonorrhoea impervious to an antibiotic have almost tripled in six months, the latest report from the National Alert System for Critical Antimicrobial Resistance (CARAlert) reveals.

The result was a “warning shot across the bow” for doctors and public health officials fighting antibiotic resistance, CARAlert’s senior medical adviser said.

Vaccine for Meningitis Shows Some Protection Against Gonorrhea

New Zealand Family Planning

Some strains of the bacterium that cause gonorrhoea are now resistant to all available antibiotics. With no new drugs on the near horizon, the disease is in desperate need of a vaccine.

Our research, published in the Lancet medical journal this week, shows that protection against gonorrhoea could come from an unexpected source – a vaccine against meningococcal group B disease.